The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer

MEHMET ZAHİD KOÇAK; MURAT ARAZ; melek karakurt eryılmaz; Mustafa Korkmaz; MEHMET ARTAÇ

doi:10.56752/Mevmedsci.2024.54

MEHMET ZAHİD KOÇAK,MURAT ARAZ,melek karakurt eryılmaz,Mustafa Korkmaz,MEHMET ARTAÇ

MEHMET ZAHİD KOÇAK: Necmettin Erbakan Üniversitesi Tıp Fakültesi
MURAT ARAZ: NECMETTİN ERBAKAN ÜNİVERSİTESİ
melek karakurt eryılmaz: Necmettin Erbakan Üniversitesi meram tıp fakültesi
Mustafa Korkmaz: meram tıp fakültesi
MEHMET ARTAÇ: NECMETTİN ERBAKAN ÜNİVERSİTESİ

Year : 2024
Vol : 4
Issue : 1
Page : 18-22

DOI : https://doi.org/10.56752/Mevmedsci.2024.54

Aim: Bevacizumab is a target therapy drug inhibiting vascular endothelial growth factor (VEGF). High serum VEGF levels are related to increased visceral and abdominal fat mass. We aim to observe the relation of body mass index (BMI) with survival in metastatic colorectal cancer (mCRC) receiving bevacizumab with cytotoxic therapy.
Methods: The study included 90 metastatic colon cancer patients receiving bevacizumab-based systemic chemotherapy in first-line treatment. Study population was stratified into two according to the BMI. Group 1 was consisted of patients with a BMI lower than 25 kg/m 2 , Group 2 was consisted of patients with a BMI higher than 25 kg/m 2 . Overall survival (OS), progression free survival (PFS), clinic characteristics, laboratory parameters, and response rates were compared between the groups.
Results: The mPFS of group 1 and group 2 were 15.8 (95% Conf. Int: 10.1-21.5) and 15.6 (95% Conf. Int:10.1-21.5) months (p=0.4), respectively. The mOS was 22.6 (95% Conf. Int: 20.1-28.8) months for group 1 and 27.61 (95% Conf. Int: 21.81-29.92) months for group 2 (p=0.02). In multivariate analysis, BMI (Hazard Ratio: 0.89, 95% Conf. Int: 0.69-0.96, p=0.024) was determined to be a risk factor for OS.
Conclusion: Increased BMI was related with more prolonged survival in patients with mCRC receiving bevacizumab. Increased BMI was found to be an independent predictive marker for improved OS.

Cite this Article As : Koçak MZ, Araz M, Karakurt Eryilmaz M, Korkmaz M, Artac M. The Relationship between Bevacizumab and Body Mass Index in Metastatic Colorectal Cancer. Mev Med Sci. 2024; 4(1): 18-22

Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.

Mevlana Tıp Bilimleri
2024, Vol4, Issue1
E-ISSN: 2757-976X

Received : 28.12.2023, Accepted : 24.04.2024 , Published Online : 26.04.2024

References

1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018;4(11):1553-68.
2. Kasi PM, Hubbard JM, Grothey A. Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. Expert Rev Gastroenterol Hepatol 2015;9(3):273-6.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004;350(23):2335-42.
4. Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin 2022;31(2):255-64.
5. Ruiz-Millo O, Albert-Mari A, Sendra-Garcia A, et al. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. J Oncol Pharm Pract 2014;20(5):341-50.
6. Martínez AM, Ferrández MJA, Rello AP, et al. Analysis of first-line treatment in older patients with metastasic colorectal cancer. J Oncol Pharm Pract 2022;28(1):74-81.
7. Ahluwalia A, K Jones M, Matysiak-Budnik T, et al. VEGF and colon cancer growth beyond angiogenesis: does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism? Curr Pharm Des 2014;20(7):1041-4.
8. Silha J, Krsek M, Sucharda P, et al. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 2005;29(11):1308-14.
9. Renfro LA, Loupakis F, Adams RA, et al. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. J Clin Oncol 2016;34(2):144.
10. Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013;119(8):1528-36.
11. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 2003;46:1483-8.
12. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut 2010;59(3):341-7.
13. Schlesinger S, Siegert S, Koch M, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. Cancer Causes Control. 2014;25:1407-18.
14. Kocak MZ. Comment on ‘Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score≥ 50% treated with front-line pembrolizumab’. Acta Oncol 2021;60(4):564-5.
15. Hopirtean C, Ciuleanu T, Cainap C, et al. Body mass index as a prognostic factor for disease progression in patients with metastatic colorectal Cancer treated with Bevacizumab based systemic therapy. Acta Endocrinol (Buchar) 2017;13(4):425.
16. Yavuz BB. Is tumor size effective in gastric cancer prognosis? Selcuk Med J 2017;34(2):51-4.
17. Konishi T, Shimada Y, Hsu M, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol 2018;4(3):309-15.
18. Kwaan MR. Postoperative CEA and other non-traditional risk factors for colon cancer recurrence: Findings from Swedish population-based data. Ann Surg Oncol 2020; 27:971-2.
19. Evrimler Ş. The Role Of MagnetIc Resonance ImagIng In The EvaluatIon Of Response Of The Locally Advanced Rectal Cancer To The ChemoradIotheraphy. Selcuk Med J 2021;37(3):209-17.
20. Kadıyoran C. ComparIson Of The GadoxetIc AcId And Gadopentate DImeglumIne EffIcIency For DetermInIng LIver Metastases By An Enhanced Mrı Of PatIents WIth GastroIntestInal MalIgnancIes. Selcuk Med J 2018;34(4):148-54
21. Dimitrova EG, Chaushev BG, Conev NV, et al. Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value in predicting outcomes of colon liver metastases and that value's association with Beclin-1 expression. Biosci Trends 2017;11(2):221-8.